[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579784":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":63,"collaborators":22,"id":65,"slug":22,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":22,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":22,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":22,"overallStatus":49,"whyStopped":22,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Northside Hospital, Inc.","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tacrolimus + MMF + Post-Transplant Cyclophosphamide","EXPERIMENTAL","Cyclophosphamide 50mg\u002Fkg\u002Fd Days +3 and +4 after transplant Tacrolimus Day -1 to Day +90 or Day +180 after transplant MMF 15mg\u002Fkg PO TID Day 0 to Day +35",[13,14,15],"Drug: Tacrolimus","Drug: Cyclophosphamide","Drug: Mycofenolate mofetil",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Tacrolimus","Begins Day -1 and continues to Day +90 or Day +180 after transplant",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Cyclophosphamide","Given Days +3 and +4 after transplant",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"Mycofenolate mofetil","Given Day 0 to Day +35 after transplant",[9],[32],{"name":33,"affiliation":34,"role":35},"Melhem Solh, MD","The Blood and Marrow Transplant Group of Georgia","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":22,"email":41},"Melh Solh, MD","CONTACT","404-255-1930","msolh@bmtga.com",{"name":43,"role":39,"phone":44,"phoneExt":22,"email":45},"Caitlin Guzowski, MBA, MHA, CCRC","404-851-8523","caitlin.guzowski@northside.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Northside Hospital","RECRUITING","Atlanta","Georgia","30342","United States",{"type":55,"coordinates":56},"Point",[57,58],-84.38798,33.749,{"lat":58,"lon":57},[61,62],{"name":43,"role":39,"phone":44,"phoneExt":22,"email":45},{"name":33,"role":35,"phone":22,"phoneExt":22,"email":22},{"type":64,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100579784",false,"NCT06828796","Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide","Inclusion Criteria:\n\n* Availability of a 5\u002F10-8\u002F10 mismatched (HLA-A, B, DR) haploidentical related donor with a negative HLA cross-match in the host vs. graft direction and willing to provide peripheral blood stem cells\n* Karnofsky status \\>\u002F= 70%\n* Hematologic malignancy requiring allogeneic transplantation\n* First allogeneic transplant only. Prior autologous transplant is allowed.\n\nExclusion Criteria:\n\n* Poor cardiac function: LVEF \\\u003C40%\n* Poor pulmonary function: FEV1 and FVC \\\u003C50% predicted\n* Poor liver function: bilirubin \\>\u002F= 3mg\u002FdL (not due to hemolysis, Gilbert's or primary malignancy)\n* Poor renal function: Creatinine \\>\u002F= 2mg\u002FdL or creatinine clearance (calculated or measured creatinine clearance is permitted) \\\u003C40mL\u002Fmin based on Traditional Cockcroft-Gault formula\n* Women of childbearing potential who currently are pregnant or who are not practicing adequate contraception\n* Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow up","ALL","18 Years","80 Years",{"count":74,"type":75},20,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process",[81,82],"Hematologic Disease and Disorders","Hematopoietic Cell Transplant","2026-04-15",{"date":85,"type":86},"2026-04-16","ACTUAL",{"date":88,"type":86},"2025-07-03",{"date":90,"type":75},"2028-06-30",{"name":5,"class":6},1]